NYSEAMERICAN:PFNX - Pfenex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.99 -0.06 (-1.48 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$3.99
Today's Range$3.98 - $4.07
52-Week Range$2.07 - $8.42
Volume40,742 shs
Average Volume145,586 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The company has collaboration agreement with Jazz Pharmaceuticals Ireland Limited and Hospira, Inc., as well as a contract agreement with The National Institute of Allergy and Infectious Diseases. Pfenex Inc. is headquartered in San Diego, California.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
Phone+1-858-3524400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees65
Outstanding Shares31,460,000
Market Cap$0.00
OptionableOptionable

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) announced its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.10. The biotechnology company earned $3.57 million during the quarter, compared to the consensus estimate of $6.30 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

2 Wall Street analysts have issued 12-month price objectives for Pfenex's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Pfenex's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 100.5% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

News headlines about PFNX stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pfenex earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Are investors shorting Pfenex?

Pfenex saw a decline in short interest in the month of November. As of November 30th, there was short interest totalling 751,459 shares, a decline of 1.6% from the November 15th total of 763,743 shares. Based on an average daily volume of 59,544 shares, the short-interest ratio is presently 12.6 days. Approximately 2.4% of the shares of the company are short sold. View Pfenex's Current Options Chain.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 46)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 60)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 50)
  • Dr. Hubert C. Chen, Advisor (Age 49)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 54)

Who are Pfenex's major shareholders?

Pfenex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (13.77%), Primecap Management Co. CA (10.85%), Blair William & Co. IL (6.33%), BlackRock Inc. (4.93%), Vanguard Group Inc. (3.88%) and Vanguard Group Inc (3.88%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Jason Grenfell-Gardner, Patricia Lady, Phillip M Schneider, Robin Campbell and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Alambic Investment Management L.P., Sanders Morris Harris LLC, TIAA CREF Investment Management LLC and C WorldWide Group Holding A S. View Insider Buying and Selling for Pfenex.

Which institutional investors are buying Pfenex stock?

PFNX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Primecap Management Co. CA, JPMorgan Chase & Co., Blair William & Co. IL and Algert Global LLC. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Jason Grenfell-Gardner, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $3.99.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Featured Article: What is the quiet period?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel